Qiagen (NYSE:QGEN) Sees Unusually-High Trading Volume - Time to Buy?

Key Points

• Qiagen shares experienced unusually high trading volume, with 6.2 million shares changing hands—152% above the prior session—and the stock rising to $49.39 from a $46.55 close.
• Analyst sentiment remains mixed: Qiagen has an average rating of “Hold” and an average price target of $43.93, below its recent trading price, although Morgan Stanley and Jefferies maintain positive ratings.
• The company exceeded quarterly expectations, reporting $0.62 EPS and $535.04 million in revenue, while institutional investors own approximately 70% of outstanding shares.

Qiagen N.V. (NYSE:QGEN - Get Free Report) shares saw unusually-high trading volume on Tuesday. 6,199,460 shares changed hands during mid-day trading, an increase of 152% from the previous session's volume of 2,460,511 shares. The stock last traded at $49.3870 and had previously closed at $46.55.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on QGEN. Berenberg Bank set a $45.50 price objective on Qiagen and gave the company a "hold" rating in a research report on Tuesday, July 14th. Morgan Stanley reaffirmed an "overweight" rating on shares of Qiagen in a research report on Friday, September 11th. Jefferies Financial Group reaffirmed a "buy" rating and issued a $48.00 target price on shares of Qiagen in a research report on Thursday, August 6th. Weiss Ratings raised Qiagen from a "hold (c-)" rating to a "hold (c)" rating in a research note on Friday, September 11th. Finally, UBS Group started coverage on shares of Qiagen in a research note on Wednesday, September 9th. They issued a "neutral" rating and a $47.00 price objective for the company. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and nine have issued a Hold rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Hold" and an average target price of $43.93.

Qiagen Price Performance

The stock's 50 day moving average price is $43.88 and its two-hundred day moving average price is $40.39. The company has a debt-to-equity ratio of 0.48, a current ratio of 2.85 and a quick ratio of 2.31. The firm has a market capitalization of $10.18 billion, a price-to-earnings ratio of 25.28, a PEG ratio of 4.59 and a beta of 0.61.

Qiagen (NYSE:QGEN - Get Free Report) last posted its quarterly earnings data on Wednesday, August 5th. The company reported $0.62 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.60 by $0.02. Qiagen had a net margin of 19.49% and a return on equity of 14.47%. The business had revenue of $535.04 million during the quarter, compared to the consensus estimate of $527.50 million. During the same period in the prior year, the firm earned $0.60 EPS. Qiagen's quarterly revenue was up .2% compared to the same quarter last year. Qiagen has set its FY 2026 guidance at 2.430- EPS. On average, equities research analysts anticipate that Qiagen N.V. will post 2.43 EPS for the current year.

Institutional Investors Weigh In On Qiagen

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Amundi lifted its position in shares of Qiagen by 12.4% during the first quarter. Amundi now owns 4,757,681 shares of the company's stock worth $190,498,000 after purchasing an additional 524,959 shares in the last quarter. Janus Henderson Group PLC acquired a new stake in shares of Qiagen in the first quarter valued at approximately $14,647,000. Troluce Capital Advisors LLC bought a new position in Qiagen in the 1st quarter worth approximately $14,514,000. Hsbc Holdings PLC bought a new position in Qiagen in the 1st quarter worth approximately $12,916,000. Finally, Dimensional Fund Advisors LP lifted its holdings in Qiagen by 20.8% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,665,011 shares of the company's stock worth $66,649,000 after buying an additional 286,665 shares in the last quarter. 70.00% of the stock is owned by institutional investors and hedge funds.

About Qiagen

QIAGEN N.V. NYSE: QGEN is a global provider of sample preparation technologies, molecular testing solutions and bioinformatics for the life sciences and molecular diagnostics markets. The company develops products that help researchers and clinical laboratories isolate, analyze and interpret DNA, RNA and other biological materials.

Its portfolio includes sample collection and purification kits, automated laboratory instruments, PCR and next-generation sequencing assays, digital PCR solutions, bioinformatics software and related consumables.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.